Skip to content

NAD+: Infusion Pharmacokinetics Are Not Proven Rejuvenation

NAD+ is a coenzyme, not a peptide. Small human infusion studies describe metabolite handling and tolerability; they do not establish general rejuvenation, disease treatment or long-term safety.

By Peptide Mag Editorial. Updated . Source and review policy.

Compound class
Nicotinamide adenine dinucleotide; not a peptide
2019 infusion pilot
Eight NAD+ participants and three controls
Identity boundary
NAD+, NADH, NR and NMN are not interchangeable interventions

The Simple Truth

Why this exists and what it’s supposed to do.

NAD+ exists in every cell you have, and the interest is that it declines with age.

NAD+ is a coenzyme that energy metabolism and DNA repair cannot run without, and measured levels fall as people get older.

What it is supposed to do: restore energy, mental clarity and cellular repair by topping up something essential that is running low. That is why it is sold as an infusion for fatigue and anti-aging.

Whether infusing it raises NAD+ where it matters, and whether that reverses anything, is unsettled. Pharmacokinetics are not proof of rejuvenation. It is also not a peptide.

Begin with the actual molecule

NAD+ is nicotinamide adenine dinucleotide, a coenzyme involved in cellular metabolism. Its biological importance does not establish that adding it by any route produces a useful clinical effect. A molecule being necessary for normal function and a treatment improving a patient's outcome are different propositions. NAD+ is also not a peptide despite appearing alongside peptide products in some catalogs.

Nicotinamide riboside, nicotinamide mononucleotide and NADH are distinct materials, commonly shortened to NR, NMN and NADH. Evidence for one should not be relabeled as direct evidence for another. The route, formulation, population and endpoint matter as well: an oral precursor trial cannot automatically validate an NAD+ infusion or an unspecified injected preparation.

The infusion pilot tracked metabolites

A 2019 pilot study tracked plasma and urine metabolites during and after an intravenous NAD+ infusion. It included eight participants in the test group and three controls. The investigators observed little early plasma change, followed by later changes in measured NAD-related compounds and urinary excretion. Their question was what happened to infused material, not whether an anti-aging treatment improved health.

These results should not be simplified to a claim that infused NAD+ all entered cells or repaired DNA. Plasma disappearance and a metabolite pattern do not independently identify every tissue destination or clinical effect. Pharmacokinetic and metabolic measurements help define exposure; they are not substitutes for controlled endpoints such as function, symptoms, disease progression or survival.

A newer retrospective comparison reported infusion symptoms

A 2026 retrospective commercial-setting study compared intravenous NAD+ and intravenous NR. It reported different tolerability profiles, including gastrointestinal symptoms, increased heart rate and chest pressure during NAD+ infusions, with symptoms resolving by infusion completion. This was not a randomized efficacy trial. The authors were employees of the commercial organization associated with the setting, a relevant conflict-of-interest context.

Short-term laboratory measures without significant change do not establish comprehensive safety. The report also contains exploratory metabolic analyses that should not be repackaged as definitive treatment benefits. A retrospective design, selected clients and limited follow-up constrain causal conclusions. Symptoms in one report do not supply an incidence estimate for every preparation or patient population, but they contradict an unqualified claim that infusions are invariably symptom-free.

Precursor research answers another question

A 2016 NR pharmacokinetic paper reported changes in the blood NAD+ metabolome after oral nicotinamide riboside. It is useful evidence that a precursor can alter measured metabolites under its study conditions. It is not a trial demonstrating direct NAD+ injection efficacy, and a higher blood measurement alone does not demonstrate meaningful improvement in aging or disease.

This distinction prevents a broad category such as NAD boosting from hiding intervention differences. Even two approaches that raise a shared measurement may have different tissue exposure, metabolism and tolerability. Comparisons require head-to-head evidence or carefully bounded inference rather than a claim that every strategy is equivalent because a biochemical pathway connects them.

What can be said without overclaiming

The selected human record supports describing infusion handling, measured metabolite changes and preliminary tolerability observations. It does not establish a general rejuvenation effect, a cure for fatigue or substance-use disorders, or safety of prolonged administration. An absence of a serious event in a small study is not a reliable exclusion of uncommon harms. This update is not an exhaustive review of every NAD-related intervention.

This guide supplies no infusion, injection, mixing or dosing instructions and does not endorse a supplier or clinic. Future studies should identify the exact molecule, formulation, route and comparator, assess outcomes that matter to patients and transparently report adverse events. Treating metabolism data as clinical proof skips the very research needed to decide whether an intervention offers worthwhile benefit.

Sources and further reading

  1. Grant et al., 2019: human NAD+ infusion metabolome pilot
  2. Reyna et al., 2026: retrospective NAD+/NR infusion tolerability comparison
  3. Trammell et al., 2016: oral NR pharmacokinetics

Continue reading